Living Outcome Oracle

Reputation as math, conditioned on outcomes.

The LOO maintains a Beta(α, β) posterior per (peptide, indication, baseline-biomarker bin, cohort cohort) tuple. Successful primary-endpoint outcomes - weighted by evidence grade and BioGate tier - increment α; null and adverse outcomes increment β. Every revealed OEA-V1 updates the relevant cells.

Posterior heatmap · P(success | peptide × indication)opacity = sample size · color = mean P
Peptide
soft-tissue recovery
metabolic / GLP-1
GH optimization
skin remodeling
cognitive resilience
longevity / circadian
antimicrobial research
BPC-157
bpc-157
77%
n≈34
23%
n≈-29
42%
n≈-22
45%
n≈16
38%
n≈-134
48%
n≈126
37%
n≈-25
TB-500 (Thymosin β-4 fragment)
tb-500
39%
n≈103
31%
n≈-51
48%
n≈12
39%
n≈-78
41%
n≈61
30%
n≈-26
28%
n≈56
GHK-Cu
ghk-cu
41%
n≈-82
16%
n≈-196
8%
n≈-420
45%
n≈-101
21%
n≈-133
44%
n≈94
40%
n≈-96
Semaglutide
semaglutide
18%
n≈-179
35%
n≈134
44%
n≈37
39%
n≈-34
48%
n≈65
5%
n≈-565
44%
n≈-75
CJC-1295 (with DAC)
cjc-1295
9%
n≈324
16%
n≈188
45%
n≈-65
11%
n≈-378
6%
n≈594
48%
n≈-82
26%
n≈46
Ipamorelin
ipamorelin
40%
n≈-81
22%
n≈94
63%
n≈27
8%
n≈789
14%
n≈67
30%
n≈-45
24%
n≈-52
Selank
selank
28%
n≈8
38%
n≈98
36%
n≈-68
12%
n≈163
47%
n≈-45
43%
n≈147
17%
n≈85
Epitalon
epitalon
47%
n≈-75
46%
n≈92
49%
n≈-34
47%
n≈25
25%
n≈234
28%
n≈-69
10%
n≈354
LL-37 (Cathelicidin)
ll-37
48%
n≈-57
21%
n≈7
13%
n≈137
31%
n≈-21
9%
n≈-520
47%
n≈40
44%
n≈20
Tirzepatide
tirzepatide
5%
n≈828
10%
n≈-295
45%
n≈60
29%
n≈-103
35%
n≈-93
17%
n≈50
13%
n≈151
Liraglutide
liraglutide
29%
n≈66
31%
n≈87
45%
n≈-22
25%
n≈257
12%
n≈-172
13%
n≈-190
42%
n≈88
Tesamorelin
tesamorelin
48%
n≈81
36%
n≈-112
53%
n≈-2
10%
n≈364
50%
n≈-42
7%
n≈-290
13%
n≈59
Sermorelin
sermorelin
9%
n≈-214
29%
n≈156
43%
n≈70
49%
n≈51
31%
n≈28
12%
n≈230
32%
n≈-132
Hexarelin
hexarelin
22%
n≈-17
36%
n≈-138
80%
n≈-18
21%
n≈-32
13%
n≈19
13%
n≈-308
17%
n≈225
MOTS-c
mots-c
24%
n≈103
75%
n≈75
49%
n≈98
39%
n≈-4
15%
n≈309
53%
n≈-30
23%
n≈-230
PT-141 (Bremelanotide)
pt-141
29%
n≈-59
47%
n≈-82
34%
n≈153
23%
n≈124
11%
n≈-165
27%
n≈194
17%
n≈145
Melanotan II
melanotan-2
20%
n≈114
49%
n≈-75
47%
n≈115
12%
n≈305
18%
n≈156
33%
n≈-42
9%
n≈-255
Delta Sleep-Inducing Peptide (DSIP)
dsip
8%
n≈-222
11%
n≈186
19%
n≈-271
46%
n≈132
35%
n≈60
20%
n≈-26
15%
n≈-173
Thymosin α1 (Zadaxin)
thymosin-alpha-1
39%
n≈-85
15%
n≈350
33%
n≈-129
22%
n≈-93
49%
n≈-69
20%
n≈-254
42%
n≈-2
KPV
kpv
47%
n≈23
42%
n≈59
32%
n≈94
21%
n≈-202
34%
n≈-145
10%
n≈133
24%
n≈86
Semax
semax
36%
n≈83
33%
n≈10
39%
n≈-76
50%
n≈101
50%
n≈6
5%
n≈631
41%
n≈-9
Teduglutide
teduglutide
47%
n≈48
12%
n≈213
7%
n≈890
26%
n≈158
48%
n≈7
6%
n≈-244
24%
n≈114
Cagrilintide
cagrilintide
8%
n≈-215
45%
n≈133
79%
n≈-66
10%
n≈134
5%
n≈-907
13%
n≈-83
42%
n≈31
Octreotide (Sandostatin)
octreotide
14%
n≈-208
47%
n≈14
24%
n≈30
7%
n≈881
49%
n≈-61
48%
n≈132
20%
n≈311
Oxytocin
oxytocin
20%
n≈143
45%
n≈13
44%
n≈-76
47%
n≈-96
45%
n≈-18
14%
n≈-39
48%
n≈-13
Dulaglutide (Trulicity)
dulaglutide
31%
n≈191
14%
n≈-289
36%
n≈-72
24%
n≈-13
41%
n≈143
30%
n≈-114
44%
n≈-119
Exenatide (Byetta/Bydureon)
exenatide
36%
n≈52
11%
n≈502
38%
n≈82
28%
n≈15
39%
n≈157
33%
n≈-82
12%
n≈-288
Retatrutide
retatrutide
33%
n≈179
15%
n≈114
42%
n≈-76
43%
n≈82
9%
n≈-551
11%
n≈99
14%
n≈165
Glucagon
glucagon
35%
n≈-71
39%
n≈76
19%
n≈157
33%
n≈-122
13%
n≈318
35%
n≈148
8%
n≈241
Mecasermin (IGF-1, Increlex)
igf-1
44%
n≈-54
29%
n≈20
38%
n≈-54
10%
n≈532
22%
n≈5
45%
n≈143
32%
n≈42
Ghrelin (acyl-ghrelin)
ghrelin
49%
n≈-4
78%
n≈70
79%
n≈50
18%
n≈-18
31%
n≈-149
41%
n≈102
16%
n≈-276
AOD-9604 (hGH 176-191)
aod-9604
17%
n≈-305
6%
n≈7
15%
n≈-314
49%
n≈37
16%
n≈-344
32%
n≈123
15%
n≈-106
Angiotensin-(1-7)
angiotensin-1-7
21%
n≈135
37%
n≈138
39%
n≈-80
15%
n≈-65
22%
n≈83
17%
n≈107
40%
n≈-83
Nesiritide (BNP, Natrecor)
nesiritide
6%
n≈-320
7%
n≈154
46%
n≈129
23%
n≈-98
24%
n≈103
14%
n≈-124
7%
n≈750
Atrial Natriuretic Peptide (ANP)
anp
30%
n≈-26
39%
n≈106
30%
n≈-45
32%
n≈-127
33%
n≈-74
8%
n≈555
23%
n≈156
Calcitonin (Salmon, Miacalcin)
calcitonin-salmon
45%
n≈23
17%
n≈-115
9%
n≈652
48%
n≈9
43%
n≈149
14%
n≈91
44%
n≈50
Teriparatide (PTH 1-34, Forteo)
teriparatide
12%
n≈143
49%
n≈56
28%
n≈-158
10%
n≈108
27%
n≈212
11%
n≈-378
22%
n≈-208
Abaloparatide (PTHrP analog, Tymlos)
abaloparatide
15%
n≈382
37%
n≈-13
76%
n≈-46
31%
n≈141
20%
n≈-33
31%
n≈-169
48%
n≈17
Desmopressin (DDAVP)
desmopressin
29%
n≈214
33%
n≈-13
13%
n≈-370
10%
n≈300
9%
n≈-155
29%
n≈-132
25%
n≈-116
Leuprolide (Lupron)
leuprolide
28%
n≈15
14%
n≈399
32%
n≈135
37%
n≈174
27%
n≈21
41%
n≈158
46%
n≈-45
Gonadorelin (GnRH, LHRH)
gonadorelin
23%
n≈136
21%
n≈-203
35%
n≈51
5%
n≈-603
38%
n≈29
7%
n≈625
39%
n≈50
Enfuvirtide (Fuzeon)
enfuvirtide
23%
n≈63
5%
n≈883
6%
n≈-406
9%
n≈341
15%
n≈256
22%
n≈-52
13%
n≈177
Secretin (ChiRhoStim)
secretin
42%
n≈68
32%
n≈182
12%
n≈385
30%
n≈-136
47%
n≈-73
27%
n≈-151
39%
n≈27
Gastrin-17
gastrin-17
22%
n≈-222
34%
n≈11
21%
n≈200
30%
n≈-75
9%
n≈692
11%
n≈483
46%
n≈111
Bivalirudin (Angiomax)
bivalirudin
29%
n≈80
35%
n≈-67
19%
n≈208
42%
n≈-70
21%
n≈-130
23%
n≈-58
28%
n≈-161
α-Melanocyte-Stimulating Hormone (α-MSH)
alpha-msh
43%
n≈139
28%
n≈-181
8%
n≈-292
34%
n≈-92
24%
n≈136
25%
n≈-183
8%
n≈-330
Substance P
substance-p
14%
n≈-294
25%
n≈69
47%
n≈-37
41%
n≈-116
28%
n≈95
19%
n≈-243
7%
n≈238
PACAP-38
pacap-38
17%
n≈-181
11%
n≈162
30%
n≈100
48%
n≈-55
14%
n≈436
23%
n≈-190
27%
n≈232
Vasoactive Intestinal Peptide (VIP)
vip
5%
n≈-731
26%
n≈-14
37%
n≈-66
33%
n≈0
38%
n≈54
39%
n≈70
17%
n≈174
Cholecystokinin-8 (CCK-8, sulfated)
cck-8
28%
n≈36
28%
n≈-86
31%
n≈-5
36%
n≈-17
21%
n≈66
41%
n≈88
30%
n≈207
P:
opacity:
→ sample size

Per-peptide posteriors

BPC-157
88.1%
β(33.8, 4.6) · 95% CI [76%, 100%]
TB-500 (Thymosin β-4 fragment)
31.6%
β(31.7, 68.7) · 95% CI [20%, 44%]
GHK-Cu
35.6%
β(41.5, 75.1) · 95% CI [24%, 48%]
Semaglutide
29.7%
β(10.8, 25.5) · 95% CI [18%, 42%]
CJC-1295 (with DAC)
35.0%
β(23.0, 42.6) · 95% CI [23%, 47%]
Ipamorelin
67.6%
β(18.0, 8.6) · 95% CI [56%, 80%]
Selank
54.5%
β(27.8, 23.2) · 95% CI [43%, 67%]
Epitalon
52.8%
β(47.0, 42.0) · 95% CI [41%, 65%]
LL-37 (Cathelicidin)
15.6%
β(12.6, 68.3) · 95% CI [4%, 28%]
Tirzepatide
26.1%
β(16.4, 46.4) · 95% CI [14%, 38%]
Liraglutide
26.6%
β(28.7, 79.1) · 95% CI [15%, 39%]
Tesamorelin
89.6%
β(60.2, 7.0) · 95% CI [78%, 100%]
Sermorelin
86.5%
β(54.7, 8.6) · 95% CI [75%, 99%]
Hexarelin
29.6%
β(21.6, 51.3) · 95% CI [18%, 42%]
MOTS-c
26.2%
β(9.5, 26.6) · 95% CI [14%, 38%]
PT-141 (Bremelanotide)
65.0%
β(63.8, 34.3) · 95% CI [53%, 77%]
Melanotan II
50.9%
β(49.4, 47.6) · 95% CI [39%, 63%]
Delta Sleep-Inducing Peptide (DSIP)
77.0%
β(56.0, 16.8) · 95% CI [65%, 89%]
Thymosin α1 (Zadaxin)
32.0%
β(24.9, 53.0) · 95% CI [20%, 44%]
KPV
5.3%
β(4.4, 78.3) · 95% CI [0%, 17%]
Semax
48.2%
β(57.9, 62.1) · 95% CI [36%, 60%]
Teduglutide
12.3%
β(11.1, 79.5) · 95% CI [0%, 24%]
Cagrilintide
39.3%
β(35.1, 54.2) · 95% CI [27%, 51%]
Octreotide (Sandostatin)
81.3%
β(25.7, 5.9) · 95% CI [69%, 93%]
Oxytocin
40.0%
β(44.0, 65.9) · 95% CI [28%, 52%]
Dulaglutide (Trulicity)
39.1%
β(17.1, 26.6) · 95% CI [27%, 51%]
Exenatide (Byetta/Bydureon)
41.1%
β(52.7, 75.5) · 95% CI [29%, 53%]
Retatrutide
82.3%
β(63.7, 13.8) · 95% CI [70%, 94%]
Glucagon
59.4%
β(69.5, 47.5) · 95% CI [47%, 71%]
Mecasermin (IGF-1, Increlex)
34.1%
β(27.5, 53.2) · 95% CI [22%, 46%]
Ghrelin (acyl-ghrelin)
41.8%
β(53.9, 75.0) · 95% CI [30%, 54%]
AOD-9604 (hGH 176-191)
68.7%
β(51.8, 23.6) · 95% CI [57%, 81%]
Angiotensin-(1-7)
46.6%
β(46.8, 53.5) · 95% CI [35%, 59%]
Nesiritide (BNP, Natrecor)
81.2%
β(67.6, 15.6) · 95% CI [69%, 93%]
Atrial Natriuretic Peptide (ANP)
40.1%
β(21.5, 32.2) · 95% CI [28%, 52%]
Calcitonin (Salmon, Miacalcin)
90.3%
β(76.9, 8.3) · 95% CI [78%, 100%]
Teriparatide (PTH 1-34, Forteo)
61.5%
β(52.4, 32.8) · 95% CI [50%, 74%]
Abaloparatide (PTHrP analog, Tymlos)
40.8%
β(13.9, 20.1) · 95% CI [29%, 53%]
Desmopressin (DDAVP)
28.4%
β(16.3, 41.0) · 95% CI [16%, 40%]
Leuprolide (Lupron)
87.5%
β(64.3, 9.2) · 95% CI [76%, 100%]
Gonadorelin (GnRH, LHRH)
29.4%
β(18.8, 45.2) · 95% CI [17%, 41%]
Enfuvirtide (Fuzeon)
91.5%
β(70.1, 6.5) · 95% CI [80%, 100%]
Secretin (ChiRhoStim)
38.3%
β(47.4, 76.4) · 95% CI [26%, 50%]
Gastrin-17
60.7%
β(73.5, 47.6) · 95% CI [49%, 73%]
Bivalirudin (Angiomax)
56.5%
β(60.1, 46.3) · 95% CI [45%, 69%]
α-Melanocyte-Stimulating Hormone (α-MSH)
68.4%
β(43.3, 20.0) · 95% CI [56%, 80%]
Substance P
71.3%
β(61.1, 24.6) · 95% CI [59%, 83%]
PACAP-38
55.6%
β(64.6, 51.7) · 95% CI [44%, 68%]
Vasoactive Intestinal Peptide (VIP)
82.0%
β(63.2, 13.9) · 95% CI [70%, 94%]
Cholecystokinin-8 (CCK-8, sulfated)
60.9%
β(76.2, 48.9) · 95% CI [49%, 73%]

Posterior update log

WhenPeptideCohortΔ posterior meanSample bumptx hash
2026-04-22 14:11BPC-157cohort-2026-q1-bpc-04+4.68%+263bcbb8e03ccbba…
2026-04-22 14:11TB-500 (Thymosin β-4 fragment)cohort-2026-q1-tb-04+4.29%+291a0e3d61190e3b…
2026-04-22 14:11GHK-Cucohort-2026-q1-ghk-04+1.80%+10c9235e9cca2360…
2026-04-22 14:11Semaglutidecohort-2026-q1-semaglutide-04+2.15%+11dba6e213daa6e0…
2026-04-22 14:11CJC-1295 (with DAC)cohort-2026-q1-cjc-04-0.83%+215cd05cad5bd05b…
2026-04-22 14:11Ipamorelincohort-2026-q1-ipamorelin-04-0.83%+29484064d9474063…